Phase II/III Study of Anti-VEGF in Neovascular AMD

NCT00021736 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

540

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Degeneration
Choroidal Neovascularization

Interventions

DRUG: EYE001 anti-VEGF aptamer

Sponsor

Eyetech Pharmaceuticals